Myasthenia Gravis PBMC

Myasthenia Gravis PBMC for Autoimmune Neuromuscular Junction Research

Human Myasthenia Gravis PBMC products are sourced from IRB-consented donors clinically diagnosed with myasthenia gravis (MG) and processed under stringent conditions within 24 hours of collection. MG is an antibody-mediated autoimmune disease of the neuromuscular junction, driven by IgG autoantibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). These cryopreserved peripheral blood mononuclear cells give direct access to the autoreactive B-cell and T-cell compartments that generate and sustain those antibodies.

Disease Biology and Why PBMC

• Autoreactive B cells and plasmablasts are the source of pathogenic AChR and MuSK autoantibodies; PBMCs allow their identification, sorting, and single-cell characterisation.
• Antigen-specific T-cell help: AChR-reactive CD4+ T cells and follicular helper T cells drive class-switched autoantibody production and can be profiled by tetramer, activation-induced marker, or cytokine assays.
• Regulatory T-cell function is impaired in MG and is a recognised research focus for tolerance-restoring therapy.
• MuSK-positive disease is IgG4-predominant, giving a distinct B-cell biology from complement-driven AChR-positive disease and a rationale for stratified cellular studies.
• B-cell-depleting and CAAR-T approaches: PBMCs support target engagement, repopulation, and cytotoxicity work for rituximab, anti-CD19/CD20, BAFF-directed, and chimeric autoantibody receptor T-cell programmes.
• Thymic biology: thymoma-associated and hyperplastic donors provide a peripheral window on a disease with a strong thymic component.

Donor Stratification Available

• Serostatus: AChR-positive, MuSK-positive, or seronegative
• Clinical subtype: ocular versus generalised MG
• Thymic pathology: thymoma-associated, thymic hyperplasia, or post-thymectomy
• Age at onset: early-onset versus late-onset disease
• Treatment status: corticosteroids, non-steroidal immunosuppressants, rituximab, complement inhibitors, FcRn antagonists, or treatment-naive
• Disease activity: stable, exacerbation, or history of myasthenic crisis
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed MG donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified MG diagnosis
• Serostatus (AChR, MuSK) where available
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Additional myasthenia gravis-specific data available upon request

Applications

• Autoreactive B-cell and plasmablast identification, sorting, and BCR repertoire sequencing
• Antigen-specific T-cell assays and T-cell receptor repertoire analysis
• Immunophenotyping by flow cytometry, spectral flow, or mass cytometry
• Regulatory T-cell frequency and suppression assays
• Single-cell RNA sequencing and bulk transcriptomic profiling
• B-cell depletion, FcRn antagonist, and CAAR-T target validation
• Ex vivo stimulation and cytokine release assays
• Biomarker discovery and drug screening in MG programmes

Other Myasthenia Gravis Specimen Types

MG donor material is also available as Myasthenia Gravis Plasma, Myasthenia Gravis Serum, Myasthenia Gravis Whole Blood, Myasthenia Gravis Leukopak, and Myasthenia Gravis Bulk Plasma.

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Myasthenia Gravis PBMC samples are shipped on dry ice and available in standard or custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. Browse all human PBMCs or request a custom disease-state collection.